Constipation News and Research

Latest Constipation News and Research

Salix presents two Phase 3 pivotal clinical trials data for non-C IBS at ACG Meeting

Salix Pharmaceuticals, Ltd. today announced the presentation of two analyses of data from its Phase 3 pivotal clinical trials, TARGET 1 and 2, demonstrating a 14-day course of XIFAXAN 550 mg (rifaximin) taken three times daily achieved adequate relief of symptoms of non-constipation irritable bowel syndrome (non-C IBS) in a significantly greater proportion of patients compared with placebo.

19 Oct 2010

Low-fructose diet effective for children with fructose intolerance and recurrent abdominal pain

Fructose intolerance, or fructose malabsorption, is common in children with recurrent or functional abdominal pain, but the condition can be effectively managed with a low‐fructose diet, according to the results of a new study unveiled today at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, Texas.

18 Oct 2010

14 global studies on osteoporosis medications FORTEO and EVISTA to be presented at ASBMR 2010

Eli Lilly and Company today announced that a total of 14 U.S. and global studies involving its osteoporosis medications, FORTEO® [teriparatide (rDNA origin) injection] and EVISTA® (raloxifene HCl tablets), will be presented at the American Society for Bone and Mineral Research (ASBMR) 2010 Annual Meeting from October 15-19 in Toronto, ON, Canada.

18 Oct 2010

Nektar presents data of NKTR-181 mu-opioid analgesic candidate at Pain 2010 Symposium

Nektar Therapeutics presented promising data today from preclinical studies of NKTR-181, a next-generation mu-opioid analgesic candidate with a novel molecular design. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious side effects associated with traditional opioid therapies.

18 Oct 2010

Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting

Nektar Therapeutics today presented new preclinical data demonstrating that NKTR-181, a mu-opioid analgesic with a novel molecular structure, dramatically reduces abuse liability while providing analgesia comparable to oxycodone and morphine.

18 Oct 2010

Acorda presents new analysis of AMPYRA tablets at ECTRIMS Congress

Acorda Therapeutics, Inc. today announced that a new analysis of AMPYRA (dalfampridine) Extended Release Tablets, 10 mg data examining walking improvement in treatment responders has been presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

15 Oct 2010

AGA's new book offers strategies to reduce IBS symptoms

A new book from the American Gastroenterological Association (AGA) offers patients with irritable bowel syndrome (IBS) a variety of strategies to lessen the burden that IBS puts on their everyday lives. IBS is a common disorder of the intestines that leads to crampy pain, gassiness, bloating and changes in bowel habits; there is no cure. The new book, "Master Your IBS," includes a variety of strategies to help patients learn how to manage their IBS symptoms and achieve greater freedom from IBS.

14 Oct 2010

Archimedes publishes results from FPNS Phase III clinical study for breakthrough cancer pain

Archimedes Pharma, an emerging specialty pharma company focused on oncology, pain, neurology and critical care sectors, today announced publication of results from a Phase III, long-term safety, tolerability and consistency of effect, clinical study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain (BTCP).

13 Oct 2010

USPTO issues Watson Notice of Allowance for key progesterone patent to treat or prevent preterm birth

Columbia Laboratories, Inc. announced today that the U.S. Patent and Trademark Office (USPTO) has issued Watson Pharmaceuticals, Inc. a Notice of Allowance for a key patent for the use of progesterone to treat or prevent preterm birth. The USPTO issues a Notice of Allowance to report that a patent application has been examined and is allowed for issuance as a patent. The patent is expected to issue within three months upon payment of required fees.

12 Oct 2010

Twenty-two physical symptoms prevalent in all types of cancers

Twenty-two physical symptoms associated with cancer - symptoms often unrecognized and undertreated - are prevalent in all types of cancers regardless of whether the patient is newly diagnosed, undergoing treatment or is a cancer survivor, according to researchers from the Regenstrief Institute and the Indiana University schools of medicine and nursing.

12 Oct 2010

Albireo reports positive results from A3309 Phase IIb study in chronic idiopathic constipation

Albireo today announced positive top-line results from a Phase IIb study in chronic idiopathic constipation (CIC) assessing efficacy and safety of three different dose levels (5, 10 and 15 mg orally once a day) of the investigational drug A3309 during an eight week trial. Analyses of the data show clinically meaningful and statistically significant improvement for patients treated with A3309 compared to placebo-treated patients.

12 Oct 2010

Chongqing Cancer Hospital commences treatment with Varian's RapidArc radiotherapy

Chongqing Cancer Hospital in Southwest China has become the first treatment center in Southwest China to offer cancer patients a faster, more precise form of image-guided radiotherapy that potentially enables doctors to improve outcomes while extending more advanced care to more patients. Clinicians at the hospital have used RapidArc® radiotherapy from Varian Medical Systems to treat patients for cancers of the nasopharynx, cervix, breast, and lung.

11 Oct 2010

Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting

Eli Lilly and Company announced today that its global Phase III trial evaluating ALIMTA (pemetrexed for injection) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) did not meet its primary endpoint for overall survival. Data were presented for the first time today at the 35th Annual Meeting of the European Society for Medical Oncology (ESMO).

11 Oct 2010

Abbott to withdraw Meridia medicine from the U.S. market

Abbott will voluntarily withdraw Meridia (sibutramine) from the U.S. market at the request of the U.S. Food and Drug Administration (FDA).

11 Oct 2010

Sucampo submits marketing application for Amitiza drug

Sucampo Pharmaceuticals, Inc. and Abbott today announced that Sucampo Pharma Ltd., a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc., has submitted a marketing application to the Japanese Pharmaceuticals and Medical Devices Agency for approval to market Amitiza (lubiprostone) 24 mcg for the treatment of chronic idiopathic constipation (CIC).

7 Oct 2010

Soy germ-based nutritional supplement helps to manage menopausal symptoms

A new women-s health, whole soy germ-based nutritional supplement containing Natural S-equol reduced the frequency of moderate to severe hot flashes and reduced muscle and joint pain in the first study of its kind among postmenopausal U.S. women, according to peer-reviewed data presented as a poster presentation at the North American Menopause Society (NAMS) Annual Meeting.

7 Oct 2010

Progenics receives NIH grant to develop novel monoclonal antibodies to treat C. difficile infection

Progenics Pharmaceuticals, Inc. today announced the award of a grant totaling $4,143,652 from the National Institutes of Health (NIH) for Progenics' program to develop novel monoclonal antibodies to treat Clostridium difficile (C. difficile) infection.

7 Oct 2010

Synergy reports positive results from plecanatide Phase IIa clinical trial for chronic constipation

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today positive results in a Phase IIa clinical trial of plecanatide (SP-304) in patients with chronic constipation. Oral plecanatide given once daily, over 14 consecutive days, at doses of 0.3, 1.0, 3.0 and 9.0 mg gave improved bowel function in patients with chronic constipation.

6 Oct 2010

Archimedes publishes FPNS clinical study results in Pain journal

Archimedes Pharma US Inc. today announced publication of results from a pivotal clinical study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain (BTCP).

5 Oct 2010

Merck to appeal against jury verdict in retrial of federal FOSAMAX case

Merck & Co., Inc. today said it will appeal a decision by the U.S. District Court for the Southern District of New York that reduced the jury verdict from $8 million to $1.5 million but denied Merck's request for judgment in its favor or a new trial in the case of Boles v. Merck, a retrial of a federal FOSAMAX case.

5 Oct 2010

Constipation News and Research

Latest Constipation News and Research

Salix presents two Phase 3 pivotal clinical trials data for non-C IBS at ACG Meeting

Low-fructose diet effective for children with fructose intolerance and recurrent abdominal pain

14 global studies on osteoporosis medications FORTEO and EVISTA to be presented at ASBMR 2010

Nektar presents data of NKTR-181 mu-opioid analgesic candidate at Pain 2010 Symposium

Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting

Acorda presents new analysis of AMPYRA tablets at ECTRIMS Congress

AGA's new book offers strategies to reduce IBS symptoms

Archimedes publishes results from FPNS Phase III clinical study for breakthrough cancer pain

USPTO issues Watson Notice of Allowance for key progesterone patent to treat or prevent preterm birth

Twenty-two physical symptoms prevalent in all types of cancers

Albireo reports positive results from A3309 Phase IIb study in chronic idiopathic constipation

Chongqing Cancer Hospital commences treatment with Varian's RapidArc radiotherapy

Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting

Abbott to withdraw Meridia medicine from the U.S. market

Sucampo submits marketing application for Amitiza drug

Soy germ-based nutritional supplement helps to manage menopausal symptoms

Progenics receives NIH grant to develop novel monoclonal antibodies to treat C. difficile infection

Synergy reports positive results from plecanatide Phase IIa clinical trial for chronic constipation

Archimedes publishes FPNS clinical study results in Pain journal

Merck to appeal against jury verdict in retrial of federal FOSAMAX case

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Constipation News and Research

Latest Constipation News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in